1. Paton WD. Compound 48/80, a potent histamine liberator. Br J Pharmac 1951; 6: 499.
2. Lindl T, Heinl-Sawaya MC, Cramer H. Effects of compound 48/80, a histamine-releasing agent, on accumulation and release of cyclic AMP in various regions of rat brain in vitro. Res Commun Chem Pathol Pharmac 1976; 13: 65-74.
3. Kamikawa Y, Shimo Y. Antagonistic effect of compound 48/80 on the inhibitory actions of morphine and methionine-enkephalin on electrically-induced contractions of guinea-pig ileum. Br J Pharmac 1978; 64: 511-518.
4. Mousli M, Beub JL, Rouot B, Landry Y, Bronner C. G proteins as targets for non-immunological histamine releasers. Agents and Actions 1991; 33: 81-83.
5. Shibanaka Y, Hayashi H, Umemura I, Fujisawa Y, Okamoto M, Tkai M, Fujita N. Eclosion hormone-mediated signal transduction in the silkworm abdominal ganglia: involvement of a cascade from inositol (1,4,5) triphosphate to cyclic GMP. Biochem Biophys Res Commun 1994; 198: 613-618.
6. Chu AJ, Walton MA, Seto A, Fox MJ, Prasad JK, Wang ZG. I. Suppression by compound 48/80 of bacterial endotoxin-inducible monocytic tissue factor activity: direct blokade of factor VII binding to THP-1 monocytes. Biochim Biophys Acta 1999; 1472: 385-394.
7. Swinyard EA, Brown WC, Goodman LS. Comparative assays of epileptic drugs in mice and rats. J Pharmac Exp Ther 1952; 106: 319-330.
8. Swinyard EA, Castellion AN, Fink GB, Goodman LS. Some neurophysiological and neuropharmacological characteristics of audiogenic-seizure susceptible mice. J Pharmac Exp Ther 1963; 140: 375-384.
9. Ewart AS. Electrically-induced convulsions. In Expermental Models of Epilepsy. A manual for Laboratory Workers. New York, Raven Press,1972; 433.
10. Yıllar DO, Akkan AG, Akcasu A, Özüner Z, Eşkazan E. Deri-altı uygulanan meperidinin farelerde maksimal elektroşok nöbetine etkisi. Cerrahpaşa Tıp Fak Derg 1989; 20: 385-390.
11. Akkan AG, Yıllar DO, Eşkazan E, Akcasu A, Özüner Z. The effect of propranolol on maximal electroshock seizures in mice. Int J Clin Pharmac Ther Toxicol 1989; 27: 255-257.
12. Eşkazan E, Yıllar DO, Akcasu A, Akkan AG. Nalokson'un fındık farelerinde maksimal elektroşok nöbetine etkisi. Cerrahpaşa Tıp Fak Derg 1990; 21: 179-186.
13. Özyazgan S, Şenses V, Utkan T, Yıldıran G, Ulak G, Gacar N, Özüner Z, Akkan AG. The effect of isradipin on maximal electroshock seizures in mice. Gen Pharmac 1998; 31: 133-135.
14. Litchfield JT, Wilcoxone F. A simplified method of evaluating dose effect experiments. J Pharmac Exp Ther 1949; 96: 99.
15. Di Rosa M, Giroud JP, Willoughby DA. Studies of the mediators of the acute inflamatory response induced in rats in different sites by carrageenin and turpentine. J Pathol 1971; 104: 15-29.
16. Frenk H. Pro-and anticonvulsant action of morphine and the endogenous opioids: involvement and interactions multiple opiate and non-opiate systems. Brain Res Rev 1983; 6: 197-210.
17. Khanna N, Khosla R, Kohli J. Opioid receptor mediated anticonvulsant effect of pentazocine. Indian J Med Sci 1998; 52: 1-7.
18. Koide S, Onishi H, Yamagami S, Kawakita Y. Effects of morphine and D-Ala2-D-Leu5-enkephaline in the seizure-susceptible El mouse. Neurochem Res 1992; 17: 779-83.
19. Frey HH. Effect of mu-and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266. Pharmacol Toxicol 1988; 62: 150-154.
20. Zhuang X, Silverman AJ, Silver R. Brain mast cell degranulation regulates blood-brain barrier. J Neurobiol 1996; 31: 393-403.